These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 12365013)

  • 41. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
    Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
    Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
    Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
    Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
    Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
    Sood AK; Lush R; Geisler JP; Shahin MS; Sanders L; Sullivan D; Buller RE; Sorosky JI
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6080-5. PubMed ID: 15447993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
    Gronlund B; Høgdall C; Hansen HH; Engelholm SA
    Cancer; 2002 Apr; 94(7):1961-7. PubMed ID: 11932898
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
    Hanjani P; Nolte S; Shahin MS
    Gynecol Oncol; 2002 May; 85(2):278-84. PubMed ID: 11972388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
    Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
    Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
    Koensgen D; Stengel D; Belau A; Klare P; Oskay-Oezcelik G; Steck T; Camara O; Mustea A; Sommer H; Coumbos A; Bogenrieder T; Lichtenegger W; Sehouli J;
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):393-400. PubMed ID: 17922272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
    Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
    Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
    Lotz JP; Pautier P; Selle F; Viens P; Fabbro M; Lokiec F; Viret F; Gligorov J; Gosse B; Provent S; Ribrag V; Micléa JM; Dosquet C; Goetschel A; Cailliot C; Lefèvre G; Genève J; Lhommé C;
    Bone Marrow Transplant; 2006 Apr; 37(7):669-75. PubMed ID: 16501591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
    Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
    J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
    Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
    Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
    Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
    J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
    Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
    J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.